CareDx, Inc. (NASDAQ:CDNA) Director Sells $192,400.00 in Stock

CareDx, Inc. (NASDAQ:CDNA - Get Free Report) Director Peter Maag sold 10,000 shares of CareDx stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $19.24, for a total transaction of $192,400.00. Following the transaction, the director now directly owns 318,846 shares in the company, valued at approximately $6,134,597.04. This represents a 3.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Peter Maag also recently made the following trade(s):

• On Wednesday, April 30th, Peter Maag sold 13,281 shares of CareDx stock. The stock was sold at an average price of $17.23, for a total value of $228,831.63.

CareDx Stock Performance

NASDAQ CDNA traded down $0.09 during trading on Monday, hitting $18.95. 730,877 shares of the company's stock traded hands, compared to its average volume of 907,962. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of 16.48 and a beta of 2.18. CareDx, Inc. has a 12-month low of $13.81 and a 12-month high of $34.84. The business has a 50 day moving average of $17.57 and a 200-day moving average of $20.00.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.03. The company had revenue of $84.69 million for the quarter, compared to analyst estimates of $84.56 million. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The company's quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.03) earnings per share. On average, analysts expect that CareDx, Inc. will post -0.9 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on CDNA. Wall Street Zen lowered CareDx from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Stephens reaffirmed an "overweight" rating and issued a $40.00 price objective on shares of CareDx in a research report on Monday, May 5th. HC Wainwright reissued a "neutral" rating and set a $25.00 target price on shares of CareDx in a research report on Monday, May 5th. Finally, The Goldman Sachs Group lowered their price target on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, CareDx has a consensus rating of "Moderate Buy" and an average price target of $30.33.

Hedge Funds Weigh In On CareDx

Hedge funds have recently made changes to their positions in the stock. Voya Investment Management LLC boosted its stake in CareDx by 12.8% in the 1st quarter. Voya Investment Management LLC now owns 24,400 shares of the company's stock worth $433,000 after purchasing an additional 2,761 shares during the period. Strs Ohio purchased a new stake in shares of CareDx in the first quarter worth about $462,000. Acadian Asset Management LLC boosted its position in shares of CareDx by 6.1% in the first quarter. Acadian Asset Management LLC now owns 359,303 shares of the company's stock valued at $6,373,000 after acquiring an additional 20,806 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in CareDx by 11.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 133,966 shares of the company's stock valued at $2,378,000 after acquiring an additional 13,619 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in CareDx by 18.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,110,014 shares of the company's stock worth $19,703,000 after acquiring an additional 170,504 shares during the period.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.